Early diagnosis of multiple sclerosis in the emergency department: Necessary for its important therapeutic implications;El diagnóstico precoz de esclerosis multiple en urgencias: Una necesidad con importantes implicaciones terapéuticas

Emergencias

Volumn 23, Issue 2, 2011, Pages 140-145

  Arbizu, Txomin ^a   Arroyo González, Rafael ^a   Casanova I Estruch, Bonaventura ^a   Fernández, Óscar ^a   Izquierdo Ayuso, Guillermo ^a   Montalbán, Xavier ^a  

^a Detección Precoz de la Esclerosis Múltiple ^*  (Spain)

Author keywords

Emergency health services; Multiple sclerosis; Neurological symptoms

Indexed keywords

EID: 79955013735     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodríguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31:333-6.
2. Kurtzke JF. Multiple sclerosis: changing times. Neuroepidemiology. 1991;10:1-8.
3. Fernández O, Luque G, San Román C, Bravo M, Dean G. The prevalence of multiple sclerosis in the Sanitary District of Vélez-Málaga, southern Spain. Neurology. 1994;44:425-9.
4. Izquierdo G, Navarro Mascarell G, Garcia Moreno JM, Dinca L. Incidence of multiple sclerosis in a nine-year period in the province of Seville (South-West Spain). Multiple Sclerosis. Committee for Treatment and Research in Multiple Sclerosis. Baltimore, Maryland, USA: Arnold; 2002. pp. 56-57.
5. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/ remitting multiple sclerosis. Lancet. 1998;352:1498-504. [Erratum, Lancet 1999;353:678].
6. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murria TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898-904.
7. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet. 2001;19:1576-82.
8. Izquierdo G, Hauw JJ, Lyon-Caen O, Marteau R, Escourolle R, Buge A, et al. Analyse clinique de 70 cas neuro-pathologiques de sclerose en plaques. Rev Neurol (Paris). 1985;141:546-52.
9. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-9.
10. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnosis criteria for multiple sclerosis: guidelines forresearch protocols. Ann Neurol. 1983;13:227-31.
11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the Internacional Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-7.
12. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389-97.
13. Polman C, Kappos L, Freedman MS, Edam G, Hartung HP, Miller DH, et al. Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. Eur J Neurol. 2008;15:113-22.
14. Fernández O, Izquierdo G, Arbizu T, Arroyo R, Casanova B, Montalbán X. Estudio descriptivo de pacientes diagnosticados de esclerosis múltiple durante el año 2004 en España: resultados finales del studio NOVO. 2006 Noviembre 22.